Protara Therapeutics, Inc. (TARA) - Price-to-Projected Revenue Ratio
The forward P/S ratio on the GURU.Markets chart illustrates the asset's valuation trend, with the current level sitting around . Protara Therapeutics operates within the biotechnology sector, focusing on the development of drugs for rare oncological diseases in US laboratories. The business is entirely non-cyclical and independent of GDP, while management under Jesse Shem effectively controls budgets and clinical programs.
Comprehensive metric breakdowns and analytics for Protara Tx (TARA)
- market price and analyst price targets:
- market capitalization indicators:
- book value of equity indicators:
- debt and liquidity data:
Debt to Equity Protara Therapeutics|TARA - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Protara Therapeutics|TARA - Company Aggregate Debts|Debt to Book Value Protara Tx|TARA - Company Long-Term Loans and Borrowings|Company Current Liabilities Protara Therapeutics|Quick Ratio protaratx.com
- net income and valuation multiples indicators:
TARA - Final Profit|Projected Future Earnings Protara Therapeutics|TARA - Market Cap to Earnings|Future Price to Earnings Protara|TARA - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Protara Tx|TARA - Operating profit EBITDA|Earnings per share for the last twelve months Protara Therapeutics|TARA - Earnings per one share for the last 12 months|Quarterly EPS earnings growth protaratx.com|TARA - Earnings per share growth rate in current year|Expected earnings per share growth for next year Protara Therapeutics
- issuer revenue and sales details:
Fundamental company analysis:Protara Therapeutics, Inc. (TARA)
For Protara Therapeutics (TARA), which is developing cancer therapies without any debt load, the projected P/S ratio reflects the market value relative to expected revenue. This indicator compares current market capitalization with future sales, allowing investors to determine the extent of asset overvaluation or identify an entry point by comparing current values with the company's historical lows and highs.
Key competitors
Price-to-Projected Revenue Ratio BeiGene ONC|Forward Price to Sales HALO|RVMD - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Ascentage Pharma Corp|CGON (CG Oncology, Inc.) - Forward Price-to-Revenue Multiple|URGN: Price to Expected Revenue Ratio|BCAX (Bicara Therapeutics) - Forward P/S Multiple|Forward P/S Multiple Personalis Inc|Price-to-Projected Revenue Ratio Erasca Corp (ERAS)|DCTH (Delcath Corp) - Forward Price to Sales|Forward P/S Multiple YMAB (Y-mAbs Therapeutics)|Forward P/S Multiple aurabiosciences.com AURA|CADL: Forward Price-to-Revenue Multiple|Forward Price to Sales ARAY (Accuray Inc)|SLS (sellaslifesciences.com) - Forward Price-to-Revenue Multiple|ACTU: Price to Expected Revenue Ratio|CTOR (Citius Oncology, Inc.) - Forward P/S Multiple|HURA: Forward Price to Sales|Forward P/S Multiple FATE|WHWK - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio TScan Therapeutics, Inc. TCRX|Forward Price to Sales CSBR|XBiotech USA - Forward P/S Multiple|CVM - Forward P/S Multiple|OS Therapies (OSTX) - Price-to-Projected Revenue Ratio|Future Price to Revenue RADX (radiopharmtheranostics.com)|ARTV (Artiva Biotherapeutics Inc.) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Adlai Nortye Limited ANL|Forward Price-to-Revenue Multiple VERU (Veru Inc.)|Forward P/S Multiple tempesttx.com (TPST)|Xilio Therapeutics - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio RENB (Renovaro Biosciences)|Mural Bio - Forward P/S Multiple|Market Cap to Expected Sales Ratio Kairos Pharma Ltd KAPA|OKUR: Forward P/S Multiple|Forward Price-to-Revenue Multiple CytoMed Therapeutics Limited|Price-to-Projected Revenue Ratio Curis Inc.|Apollomics Corp (APLM) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple THAR (Tharimmune Corp)|Price to Expected Revenue Ratio ADVB|Forward P/S Multiple GNPX (Genprex, Inc.)|Forward P/S Multiple Calidi Biotherapeutics Inc. CLDI|SBFM - Price-to-Projected Revenue Ratio|Forward Price to Sales XBIO (Xenetic Biosciences)|SLRX: Forward P/S Multiple|Kitov Pharma (PPBT) - Forward P/S Multiple|AONC (American Oncology Network Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple beigene.com (BGNE)|Forward P/S Multiple CKPT|Forward P/S Multiple elevationoncology.com (ELEV)|Price-to-Projected Revenue Ratio iCAD ICAD|IKNA: Market Cap to Projected Revenue|Notable Labs, Ltd. - Forward P/S Multiple|Viracta Therapeutics (VIRX) - Forward Price-to-Revenue Multiple|MOR: Forward P/S Multiple|Market Cap to Future Revenue Ratio NAYA Biosciences Inc (NAYA)|Price-to-Projected Revenue Ratio Ascentage Pharma Group Ltd
